Related Experiment Videos
Captopril effect on non-diabetic glomerular albuminuria
L Nieto Cisneros1, A Viniegra, G Castro-Martínez
1Departamento de Medicina Interna, Hospital General de Zona Gabriel Mancera, México D.F.
Archivos De Investigacion Medica
|July 1, 1991
Summary
Captopril effectively reduced urinary albumin and increased serum albumin in non-diabetic patients with glomerular albuminuria. This suggests captopril is a valuable treatment option for non-diabetic kidney disease with proteinuria.
Area of Science:
- Nephrology
- Pharmacology
Background:
- Glomerular albuminuria in non-diabetic patients is a significant indicator of kidney disease.
- Effective management strategies for non-diabetic albuminuria are crucial to prevent disease progression.
Purpose of the Study:
- To evaluate the effectiveness of captopril in treating glomerular albuminuria in non-diabetic individuals.
- To assess the impact of captopril on urinary and serum albumin levels.
Main Methods:
- A study involving 16 non-diabetic patients with proteinuria exceeding 1 g/day.
- Administration of captopril at a dosage of 50 mg/day over a 4-month follow-up period.
Main Results:
- A statistically significant decrease in urinary albumin levels (p < 0.001) was observed.
- A concurrent increase in serum albumin levels was noted during the treatment period.
Conclusions:
- Captopril demonstrates effectiveness in reducing albuminuria in non-diabetic patients.
- The findings support the use of captopril as part of the treatment regimen for non-diabetic kidney disease with albuminuria.